AstraZeneca said on Tuesday (Dec 26) it will buy China-based Gracell Biotechnologies for up to US$1.2 billion as the British pharma company furthers its cell therapy ambitions.

The cash deal aimed at bolstering AstraZeneca’s portfolio values US-listed Gracell at US$2 per ordinary share or US$10 per American Depositary Shares of Gracell, plus a non-tradable contingent value right of US$0.30 per ordinary share, if certain regulatory milestones are met.

“The proposed acquisition of Gracell will complement AstraZeneca’s existing capabilities and previous investments in cell therapy, where we have established our presence in CAR-T and T-cell receptor therapies in solid tumours”, AstraZeneca’s Oncology R&D Vice President Susan Galbraith said in a statement.

Autologous CAR-T is a cell therapy created by reprogramming a patient’s immune T-cells, a key part of the body’s immune response, to target disease-causing cells. Gracell’s FasTCAR platform enhances T-cell fitness and could potentially improve the effectiveness of treatment in patients.

AstraZeneca will also acquire Gracell’s cash, cash equivalents and short-term investments of US$234.1 million as of Sept 30 2023 and the deal is expected to close in the first quarter of 2024, according to the statement.

Gracell will operate as a wholly owned subsidiary of the London-listed company with operations in China and the US, without impacting AstraZeneca’s financial guidance for 2023, the companies said. REUTERS

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

Sign UpVIEW ALL